EUCTR2009-015614-21-IT
Active, not recruiting
Not Applicable
Stereotactic accelerated radiotherapy concurrent with Temozolomide chemotherapy in newly diagnosed glioblastoma - ND
ISTITUTO NEUROLOGICO CARLO BESTA0 sitesDecember 4, 2009
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ISTITUTO NEUROLOGICO CARLO BESTA
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\* Newly diagnosed supra\-tentorial glioblastoma, surgically resected \* Radiologically proved surgical resection of the tumor mass \* Age between 18 and 65 years \* Karnofski Performance Status ≥ 70 \* Bone marrow, liver and kidney standard functionality \* No concomitant infections \* Life expectancy \> 12 weeks \* Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •\* Brain neoplasia for which histological diagnosis is not available \* Newly diagnosed glioblastoma, obtained by biopsy \* Glioblastoma with dissemination subependimal \* Tissue histology not available \* Age \> 65 and \<18\-aa \* Karnofski Performance Status \<70 \* Severely impaired bone marrow function, liver, kidney \* Co\-infected \* Pregnancy \* Pregresso chemotherapy and / or radiotherapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Addition of stereotactic radiotherapy to the standard FOLFIRINOX treatment in locally advanced pancreatic cancer patients to determine efficacy and feasability (LAPC-1)locally advanced pancreatic carcinomaPancreatic cancer1001567410017991NL-OMON44466Stichting Leveronderzoek51
Unknown
Not Applicable
Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.locally advanced pancreatic cancerpancreatic neoplasmFOLFIRINOXstereotactic radiotherapyNL-OMON27030Foundation for Liver and Gastrointestinal Research51
Active, not recruiting
Phase 2
SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.Oligometastatic or oligoprogressive ovarian, fallopian tube or primary peritoneal carcinomaCancerISRCTN13282459Institute of Cancer Research Clinical Trial & Statistics Unit42
Recruiting
Phase 1
Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate cancer. Phase II Spanish study, prospective, multicenter. (OLIGORESIST)Oligometastatic patients with castration-resistant prostate cancerTherapeutic area: Diseases [C] - Male Urogenital Diseases [C12]Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-505024-62-01Instituto de investigación en Oncología radioterápica FEOR (Fundación Española de Oncología RT)51
Completed
Phase 2
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trialcancer spread to other parts of the bodymetastatic cancer10027476NL-OMON37922Vrije Universiteit Medisch Centrum20